Independent pharmacies adapt to specialty drugs, biosimilars, cold-chain, and REMS demands.
|Articles|May 7, 2007
Another formulation cleared for Enbrel
Manufacturers Amgen and Wyeth have received approval from the FDA for a 25 mg/0.5 ml single-use prefilled syringe of etanercept (Enbrel).
Advertisement
Manufacturers Amgen and Wyeth have received approval from the FDA for a 25 mg/0.5 ml single-use prefilled syringe of etanercept (Enbrel). The new syringe will offer patients another dosing option and will make the fourth formulation available for the biologic. Etanercept is also available as a 50-mg/ml SureClick autoinjector, a 25-mg multiple-use vial, and a 50-mg prefilled syringe.
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
During American Pharmacists Month, pharmacy teams reflect on their roles and explore ways to enhance patient care.
Lara Zakaria, PharmD, MS, CNS, FMCP, discusses her perspectives regarding the emergence of wearable technology among community pharmacy patients.
Diabetes medication experts focus on practical access and pharmacist counseling considerations for adults on obesity medication.
The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
Melissa McGivney, PharmD, FAPhA, FCCP, helps celebrate American Pharmacists Month and the innovation driving the profession forward amongst US communities.
Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.
The novel tool can be used to inform vaccine policy, monitor impact, and essentially strengthen overall surveillance.
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Improve Access, Safe Use of Obesity Medications
2
FDA Approves New Drug for HSV Lesions in Adults
3
Is Your Independent Pharmacy Ready for New Therapies and Innovations?
4
Wearable Tech as a Revenue, Clinical Service Opportunity for Pharmacists | NCPA 2026
5